LSD microdosing carries physiological and psychological risks
Current scientific literature and reviews indicate that LSD microdosing carries potential psychological risks (such as anxiety and emotional vulnerability) and physiological safety concerns (such as cardiovascular or receptor-mediated risks), though evidence remains mixed and heavily dependent on study design.
The claim states that LSD microdosing carries physiological and psychological risks. Multiple reviews and preclinical studies (e.g., [0], [2], [3], [5]) document both physiological concerns (such as potential 5-HT2B receptor-mediated cardiac risks and physical discomfort) and psychological risks (such as anxiety and emotional vulnerability). Thus, the claim is well supported by the literature.
M. Tagen, D. Mantuani, Liron van Heerden, A. Holstein, L. Klumpers, R. Knowles. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. 2023. https://doi.org/10.1177/02698811231190865
Paper 0 discusses the theoretical physiological risk of valvular heart disease resulting from the chronic activation of serotonin 5-HT2B receptors by psychedelic microdoses.
See more details
David F Lo, Hasan Zia, Pranetha Rajkumar, Adarsh Thakur, Heather O'Donnell. Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.. 2024. https://doi.org/10.4088/pcc.23r03581
Paper 2 notes that while microdosing offers potential mental health benefits, users frequently report physiological discomfort and increased anxiety as challenges.
I. Totomanova, E. Haijen, P. Hurks, J. Ramaekers, K. Kuypers. Between enhancement and risk: A critical review of psychedelic microdosing.. 2025. https://doi.org/10.1016/j.copsyc.2025.102129
Paper 3 reviews both clinical and observational findings, noting that adverse effects such as anxiety, physical discomfort, and cognitive disruption are frequently reported.
Omidian H, Omidian A. Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.. 2025. https://doi.org/10.3390/ph18040499
Paper 5 reviews LSD's clinical potential but explicitly highlights safety considerations, including cardiovascular risks, emotional vulnerability, and hallucinogen-persisting perception disorder.
Effinger DP, Schalk SS, King JL, Wallingford JR, O'Connell CK, Calderon JR, Kopecky BJ, McCorvy JD, Thompson SM. Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice.. 2025. https://doi.org/10.1021/acsptsci.5c00202
Paper 7 evaluates the physiological risk of microdosing LSD on cardiovascular health, though noting no significant ventricular or valvular remodeling in its specific mouse model.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt